Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMRN: Amarin Corporation plc -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (25)	10/27/2008 12:11:42 AM
From: Mike McFarland	Respond to of 49

end of second quarter Turning to our balance sheet, Amarin has approximately $26.3 million of cash at the end of the quarter and in shares we have $27 million ordinary in issue and options and warrants outstanding to purchase approximately $4.8 million shares. now at 80 cents, down from $3 six months ago, like a lot of things trading for a bit less than cash. The yahoo industry group Drug Manufacturers - Other has more than a dozen stocks trading below book value per share. I see other bargains to put on lists. There are around 40 in the biotechnology group.